In short
Clinical trials are investigating Alpha1H in adults with non-muscle invasive bladder cancer who are waiting for transurethral surgery. These studies look at safety and early signs of benefit, including tumor response before surgery.
Key points
- Clinical trials of Alpha1H are studying adults with non-muscle invasive bladder cancer who are waiting for surgery to remove the tumor. The study is early stage and listed as Phase 1, with the title also describing it as Phase I/II. It compares Alpha1H with placebo to see whether the treatment is safe and whether it shows signs of helping the tumor before surgery. The main measurements include side effects, vital signs, ECG, lab tests, urine cell shedding, cystoscopy findings, and tumor tissue analysis. The trial was completed and enrolled 76 people.
Trial overview
The available trial studied Alpha1H in adult patients with non-muscle invasive bladder cancer who were waiting for transurethral surgery to remove the tumor. The study was described as a Phase I/II randomized study in the title and as Phase 1 in the trial record, which means it was an early clinical trial focused on safety and first signs of benefit. The trial status was Completed, and the enrollment was 76 participants.
Who could join the study
The target population was adults with bladder cancer that had not grown into the muscle layer of the bladder wall. The study focused on people who were already scheduled for surgery through the urethra, so the treatment was tested before the planned tumor removal.
This type of study is important because it looks at patients at a specific point in care: before surgery, when researchers can measure the tumor directly and compare changes over time.
What was studied
The study compared Alpha1H with a placebo product for Alpha1H. A placebo is a look-alike treatment used for comparison, so researchers can better judge whether the study drug has an effect.
Alpha1H was given by intravesical use, which means it was placed directly into the bladder. The main aim was to evaluate whether this approach was safe and whether it could help change the tumor before surgery.
Main endpoints and safety checks
The main safety endpoint was adverse events, meaning any medical problems or unwanted effects seen during the study and for 30 days after the last treatment or placebo dose. The trial also checked vital signs, ECG, and laboratory parameters to monitor general safety.
To look for tumor response, the study measured cell shedding in urine, which was used as a biomarker, meaning a measurable sign that may show how the tumor is reacting to treatment. Researchers also used cystoscopy imaging to see the tumor in the bladder and examined the removed tissue with histopathology after surgery.
The trial description says the researchers expected Alpha1H to trigger tumor cell shedding into urine and to cause changes in tumor size and shape, based on earlier studies and a murine bladder cancer model. In this study report, those effects were part of what the researchers planned to look for, not proven results.
How the trial was designed
This was an interventional trial, which means the researchers gave a study treatment and then measured the results. It was also randomized, so participants were assigned to a study group by chance rather than by choice.
Randomized studies help compare treatments more fairly because they reduce bias, which is when outside factors affect the results. In this trial, the comparison was between Alpha1H and placebo before the planned operation.